Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Hayashi S, Tachibana S, Maeda T, Yamashita M, Shirasugi I, Yamamoto Y, Yamada H, Okano T, Nishimura K, Ueda Y, Jinnno S, Saegusa J, Yamamoto W, Murata K, Fujii T, Hata K, Yoshikawa A, Ebina K, Etani Y, Yoshida N, Amuro H, Hashimoto M, Hara R, Katayama M, Okano T, Kuroda R. Hayashi S, et al. Among authors: shirasugi i. Rheumatology (Oxford). 2023 Nov 1:kead543. doi: 10.1093/rheumatology/kead543. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37924201
Severe Lupus Myocarditis Preceded by Mesalazine-induced Lupus.
Yamashita M, Nishimura K, Shirasugi I, Ichise Y, Ueda Y, Saegusa J. Yamashita M, et al. Among authors: shirasugi i. Intern Med. 2023 Mar 15;62(6):929-933. doi: 10.2169/internalmedicine.9613-22. Epub 2022 Aug 10. Intern Med. 2023. PMID: 35945022 Free PMC article.
Demographic, Physical, and Psychological Determinants of Patient Experience with Subcutaneous Self-Injection in Patients with Rheumatoid Arthritis: Structural Equation Modeling Approach.
Onishi A, Kaizu M, Shirasugi I, Yagyu T, Ueda Y, Sakai Y, Miura Y, Saegusa J. Onishi A, et al. Among authors: shirasugi i. Patient Prefer Adherence. 2023 Jul 3;17:1551-1559. doi: 10.2147/PPA.S413871. eCollection 2023. Patient Prefer Adherence. 2023. PMID: 37426046 Free PMC article.
Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
Shirasugi I, Onishi A, Nishimura K, Yamamoto W, Murakami K, Onizawa H, Maeda Y, Ebina K, Son Y, Amuro H, Katayama M, Hara R, Nagai K, Hiramatsu Y, Hashimoto M, Okano T, Maeda T, Hayashi S, Sendo S, Jinno S, Yamamoto Y, Yamada H, Ueda Y, Saegusa J. Shirasugi I, et al. Int J Rheum Dis. 2024 Mar;27(3):e15097. doi: 10.1111/1756-185X.15097. Int J Rheum Dis. 2024. PMID: 38439176
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, Maeda Y, Jinno S, Shirasugi I, Son Y, Amuro H, Katayama M, Hara R, Hata K, Yoshikawa A, Yamamoto W, Tachibana S, Hayashi S, Etani Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Watanabe R, et al. Among authors: shirasugi i. Rheumatology (Oxford). 2024 May 9:keae265. doi: 10.1093/rheumatology/keae265. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38724245
Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, Son Y, Shirasugi I, Maeda T, Katsushima M, Hashimoto M, Etani Y, Itami T, Nozaki Y, Onizawa H, Fujii T, Murakami K, Murata K, Tanaka M, Matsuda S, Morinobu A. Nakayama Y, et al. Among authors: shirasugi i. Clin Exp Med. 2024 May 10;24(1):97. doi: 10.1007/s10238-024-01360-w. Clin Exp Med. 2024. PMID: 38727756 Free PMC article.